Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) tinted loss of -0.46% (-0.06 points) to US$12.96. The volume of 0.15 Million shares climbed down over an trading activity of 183.15 Million shares. EPS ratio determined by looking at last 12 month figures is -2.11. Over the same time span, the stock marked US$24.38 as its best level and the lowest price reached was US$6.3. The corporation has a market cap of US$451.27 Million.

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS)’s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -67.1 percent while most common profitability ratio return on investment (ROI) was -83.7 percent. The company’s institutional ownership is monitored at 71.8 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 2 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 2 think it is Hold. Recently, analysts have updated the overall rating to 2. 3 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Rudolph Technologies, Inc. (NYSE:RTEC) is worth US$1.1 Billion and has recently fallen -0.46% to US$32.3. The latest exchange of 0.14 Million shares is below its average trading activity of 219.97 Million shares. The day began at US$32.5 but the price moved to US$32 at one point during the trading and finally capitulating to a session high of US$32.8. The stock tapped a 52-week high of US$34.55 while the mean 12-month price target for the shares is US$34.33.

Currently, the stock carries a price to earnings ratio of 20.56, a price to book ratio of 2.92, and a price to sales ratio of 4.1. For the past 5 years, the company’s revenue has grown 3.1%, while the company’s earnings per share has grown -0.2%. With an institutional ownership near 92.4%, it carries an earnings per share ratio of 1.57.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 2 brokerage firms polled by Factset Research. At present, 1 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 1 analysts call it Underweight, while 2 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.17.